Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biomarkers For Pancreatic Cancer To Be Tested In Multi-drug Collaborative Study

Executive Summary

Patient advocacy group is spearheading the genomics-driven trial, which will assess if stratification may finally be possible in pancreatic cancer.


Related Content

AML Master Protocol For Precision Medicine Developed By Nonprofit And US FDA
NewLink’s HyperAcute Program In Limbo After Pancreatic Trial Blow-Up
Abraxane Drives Growth In Potential $1bn Pancreatic Cancer Market
Genomics-Driven Trials Built To Be Fast And Flexible
More Hope, And More Demands, For Pancreatic Cancer Pipeline


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst